Compare ArcelorMittal SA (MT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Novo Nordisk A/S — how do they compare? ArcelorMittal SA trades at $66.25 (market cap $50.01B), while Novo Nordisk A/S trades at $49.31 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 4.4× ArcelorMittal SA's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| MT | NVO | |
|---|---|---|
Market Cap | $50.01B | $220.53B |
Sector | Basic Materials | Health |
52-Week High | $71.65 | $71.70 |
52-Week Low | $30.39 | $35.29 |
Enterprise Value | $59.33B | $239.49B |
Dividend Yield | 0.91% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $65.80, down 0.98% today, with a bullish technical outlook supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.24 and P/S of 0.81. Recent corporate developments include ongoing share buybacks and a strategic AI collaboration with AWS to enhance operational efficiency.
The outlook for MT is cautiously optimistic, driven by earnings strength and cost initiatives, but faces risks from cyclical steel demand and high capital expenditures. Analyst sentiment is mixed with 50% buy ratings, suggesting potential upside if operational improvements continue, though investors should monitor global economic conditions impacting steel prices.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
